New Biomarkers for Renal Transporter‐Mediated Drug–Drug Interactions: Metabolomic Effects of Cimetidine, Probenecid, Verapamil, and Rifampin in Humans
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3414 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Arne Gessner und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. Hauptthemen laut MEDLINE: Probenecid, Cimetidine, Rifampin, Drug Interactions. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The inhibition of renal transport proteins organic cation transporter 2 (OCT2), multidrug and toxin extrusion proteins (MATE1, MATE2‐K), and organic anion transporters (OAT1, OAT3) causes clinically relevant drug–drug interactions (DDI). Endogenous biomarkers could be used to improve risk prediction of such renal DDIs. While a number of biomarkers for renal DDIs have been described so far, multiple criteria for valid biomarkers have frequently not been investigated, for example, specificity, metabolism, or food effects. Therefore, there is a need for novel biomarkers of renal DDIs. Here, we investigated the global metabolomic effects following the administration of two classical inhibitors of renal transport proteins [cimetidine (OCT2/MATEs), probenecid (OATs)] in human plasma and urine of healthy volunteers. Additionally, we investigated metabolomic effects of two inhibitors of other transporters [verapamil (P‐glycoprotein), rifampin (organic anion transporting polypeptides)] as controls. This analysis shows that both cimetidine and probenecid affect compounds involved in caffeine metabolism, carnitines, and sulfates. Hierarchical cluster analysis of the effects of all four inhibitors on endogenous compounds identified multiple promising new sensitive and specific biomarker candidates for OCT2/MATE‐ or OAT‐mediated DDIs. For OCT2/MATEs, 5‐amino valeric acid betaine (median log 2 ‐fold change of estimated renal elimination: −3.62) presented itself as a promising candidate. For OATs, estimated renal elimination of 7‐methyluric acid and cinnamoylglycine (median log 2 ‐fold changes −3.10 and −1.92, respectively) was both sensitive and specific. This study provides comprehensive information on metabolomic effects of transport protein inhibition in humans and identifies putative new sensitive and specific biomarkers for renal transporter‐mediated DDIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- FAU NeW - Research Center New Bioactive Compounds, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- Department of Chemistry and Pharmacy, Pharmaceutical Chemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
ORCID-Profile: Arne Gessner, Jörg König, Pia Wenisch, Markus R Heinrich, Peter Stopfer, Martin F Fromm, Fabian Müller
Zitieren
APA
Gessner, A., König, J., Wenisch, P., Heinrich, M. R., Stopfer, P., Fromm, M. F., & Müller, F. (2025). New Biomarkers for Renal Transporter‐Mediated Drug–Drug Interactions: Metabolomic Effects of Cimetidine, Probenecid, Verapamil, and Rifampin in Humans. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3414
Vancouver
Gessner A, König J, Wenisch P, Heinrich MR, Stopfer P, Fromm MF, et al. New Biomarkers for Renal Transporter‐Mediated Drug–Drug Interactions: Metabolomic Effects of Cimetidine, Probenecid, Verapamil, and Rifampin in Humans. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3414
BibTeX
@article{Gessner2025,
author = {Gessner, Arne and König, Jörg and Wenisch, Pia and Heinrich, Markus R and Stopfer, Peter and Fromm, Martin F and Müller, Fabian},
title = {New Biomarkers for Renal Transporter‐Mediated Drug–Drug Interactions: Metabolomic Effects of Cimetidine, Probenecid, Verapamil, and Rifampin in Humans},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3414}
}
EUVIMED